Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy

Min Xie, Yongli Kong, Wei Tan, Herman May, Pavan K. Battiprolu, Zully Pedrozo, Zhao Wang, Cyndi Morales, Xiang Luo, Geoffrey Cho, Nan Jiang, Michael E Jessen, John J Warner, Sergio Lavandero, Thomas G. Gillette, Aslan T Turer, Joseph A Hill

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

BACKGROUND - : Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor approved for cancer treatment by the US Food and Drug Administration, will blunt reperfusion injury. METHODS AND RESULTS - : Twenty-one rabbits were randomly assigned to 3 groups: (1) vehicle control, (2) SAHA pretreatment (1 day before and at surgery), and (3) SAHA treatment at the time of reperfusion only. Each arm was subjected to ischemia/reperfusion surgery (30 minutes coronary ligation, 24 hours reperfusion). In addition, cultured neonatal and adult rat ventricular cardiomyocytes were subjected to simulated ischemia/reperfusion to probe mechanism. SAHA reduced infarct size and partially rescued systolic function when administered either before surgery (pretreatment) or solely at the time of reperfusion. SAHA plasma concentrations were similar to those achieved in patients with cancer. In the infarct border zone, SAHA increased autophagic flux, assayed in both rabbit myocardium and in mice harboring an RFP-GFP-LC3 transgene. In cultured myocytes subjected to simulated ischemia/reperfusion, SAHA pretreatment reduced cell death by 40%. This reduction in cell death correlated with increased autophagic activity in SAHA-treated cells. RNAi-mediated knockdown of ATG7 and ATG5, essential autophagy proteins, abolished SAHA's cardioprotective effects. CONCLUSIONS - : The US Food and Drug Administration-approved anticancer histone deacetylase inhibitor, SAHA, reduces myocardial infarct size in a large animal model, even when delivered in the clinically relevant context of reperfusion. The cardioprotective effects of SAHA during ischemia/reperfusion occur, at least in part, through the induction of autophagic flux.

Original languageEnglish (US)
Pages (from-to)1139-1151
Number of pages13
JournalCirculation
Volume129
Issue number10
DOIs
StatePublished - Mar 11 2014

Fingerprint

Histone Deacetylases
Autophagy
Reperfusion Injury
Cardiac Myocytes
Reperfusion
Ischemia
Histone Deacetylase Inhibitors
United States Food and Drug Administration
Cell Death
vorinostat
Rabbits
Nonpenetrating Wounds
RNA Interference
Transgenes
Muscle Cells
Myocardial Ischemia
Ligation
Neoplasms
Myocardium
Therapeutics

Keywords

  • Autophagy
  • cell death
  • histone deacetylases
  • myocardial infarction
  • reperfusion injury

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. / Xie, Min; Kong, Yongli; Tan, Wei; May, Herman; Battiprolu, Pavan K.; Pedrozo, Zully; Wang, Zhao; Morales, Cyndi; Luo, Xiang; Cho, Geoffrey; Jiang, Nan; Jessen, Michael E; Warner, John J; Lavandero, Sergio; Gillette, Thomas G.; Turer, Aslan T; Hill, Joseph A.

In: Circulation, Vol. 129, No. 10, 11.03.2014, p. 1139-1151.

Research output: Contribution to journalArticle

Xie, M, Kong, Y, Tan, W, May, H, Battiprolu, PK, Pedrozo, Z, Wang, Z, Morales, C, Luo, X, Cho, G, Jiang, N, Jessen, ME, Warner, JJ, Lavandero, S, Gillette, TG, Turer, AT & Hill, JA 2014, 'Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy', Circulation, vol. 129, no. 10, pp. 1139-1151. https://doi.org/10.1161/CIRCULATIONAHA.113.002416
Xie, Min ; Kong, Yongli ; Tan, Wei ; May, Herman ; Battiprolu, Pavan K. ; Pedrozo, Zully ; Wang, Zhao ; Morales, Cyndi ; Luo, Xiang ; Cho, Geoffrey ; Jiang, Nan ; Jessen, Michael E ; Warner, John J ; Lavandero, Sergio ; Gillette, Thomas G. ; Turer, Aslan T ; Hill, Joseph A. / Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. In: Circulation. 2014 ; Vol. 129, No. 10. pp. 1139-1151.
@article{6cfa989c5f9746b9bf6f8629bb8c8052,
title = "Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy",
abstract = "BACKGROUND - : Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor approved for cancer treatment by the US Food and Drug Administration, will blunt reperfusion injury. METHODS AND RESULTS - : Twenty-one rabbits were randomly assigned to 3 groups: (1) vehicle control, (2) SAHA pretreatment (1 day before and at surgery), and (3) SAHA treatment at the time of reperfusion only. Each arm was subjected to ischemia/reperfusion surgery (30 minutes coronary ligation, 24 hours reperfusion). In addition, cultured neonatal and adult rat ventricular cardiomyocytes were subjected to simulated ischemia/reperfusion to probe mechanism. SAHA reduced infarct size and partially rescued systolic function when administered either before surgery (pretreatment) or solely at the time of reperfusion. SAHA plasma concentrations were similar to those achieved in patients with cancer. In the infarct border zone, SAHA increased autophagic flux, assayed in both rabbit myocardium and in mice harboring an RFP-GFP-LC3 transgene. In cultured myocytes subjected to simulated ischemia/reperfusion, SAHA pretreatment reduced cell death by 40{\%}. This reduction in cell death correlated with increased autophagic activity in SAHA-treated cells. RNAi-mediated knockdown of ATG7 and ATG5, essential autophagy proteins, abolished SAHA's cardioprotective effects. CONCLUSIONS - : The US Food and Drug Administration-approved anticancer histone deacetylase inhibitor, SAHA, reduces myocardial infarct size in a large animal model, even when delivered in the clinically relevant context of reperfusion. The cardioprotective effects of SAHA during ischemia/reperfusion occur, at least in part, through the induction of autophagic flux.",
keywords = "Autophagy, cell death, histone deacetylases, myocardial infarction, reperfusion injury",
author = "Min Xie and Yongli Kong and Wei Tan and Herman May and Battiprolu, {Pavan K.} and Zully Pedrozo and Zhao Wang and Cyndi Morales and Xiang Luo and Geoffrey Cho and Nan Jiang and Jessen, {Michael E} and Warner, {John J} and Sergio Lavandero and Gillette, {Thomas G.} and Turer, {Aslan T} and Hill, {Joseph A}",
year = "2014",
month = "3",
day = "11",
doi = "10.1161/CIRCULATIONAHA.113.002416",
language = "English (US)",
volume = "129",
pages = "1139--1151",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy

AU - Xie, Min

AU - Kong, Yongli

AU - Tan, Wei

AU - May, Herman

AU - Battiprolu, Pavan K.

AU - Pedrozo, Zully

AU - Wang, Zhao

AU - Morales, Cyndi

AU - Luo, Xiang

AU - Cho, Geoffrey

AU - Jiang, Nan

AU - Jessen, Michael E

AU - Warner, John J

AU - Lavandero, Sergio

AU - Gillette, Thomas G.

AU - Turer, Aslan T

AU - Hill, Joseph A

PY - 2014/3/11

Y1 - 2014/3/11

N2 - BACKGROUND - : Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor approved for cancer treatment by the US Food and Drug Administration, will blunt reperfusion injury. METHODS AND RESULTS - : Twenty-one rabbits were randomly assigned to 3 groups: (1) vehicle control, (2) SAHA pretreatment (1 day before and at surgery), and (3) SAHA treatment at the time of reperfusion only. Each arm was subjected to ischemia/reperfusion surgery (30 minutes coronary ligation, 24 hours reperfusion). In addition, cultured neonatal and adult rat ventricular cardiomyocytes were subjected to simulated ischemia/reperfusion to probe mechanism. SAHA reduced infarct size and partially rescued systolic function when administered either before surgery (pretreatment) or solely at the time of reperfusion. SAHA plasma concentrations were similar to those achieved in patients with cancer. In the infarct border zone, SAHA increased autophagic flux, assayed in both rabbit myocardium and in mice harboring an RFP-GFP-LC3 transgene. In cultured myocytes subjected to simulated ischemia/reperfusion, SAHA pretreatment reduced cell death by 40%. This reduction in cell death correlated with increased autophagic activity in SAHA-treated cells. RNAi-mediated knockdown of ATG7 and ATG5, essential autophagy proteins, abolished SAHA's cardioprotective effects. CONCLUSIONS - : The US Food and Drug Administration-approved anticancer histone deacetylase inhibitor, SAHA, reduces myocardial infarct size in a large animal model, even when delivered in the clinically relevant context of reperfusion. The cardioprotective effects of SAHA during ischemia/reperfusion occur, at least in part, through the induction of autophagic flux.

AB - BACKGROUND - : Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor approved for cancer treatment by the US Food and Drug Administration, will blunt reperfusion injury. METHODS AND RESULTS - : Twenty-one rabbits were randomly assigned to 3 groups: (1) vehicle control, (2) SAHA pretreatment (1 day before and at surgery), and (3) SAHA treatment at the time of reperfusion only. Each arm was subjected to ischemia/reperfusion surgery (30 minutes coronary ligation, 24 hours reperfusion). In addition, cultured neonatal and adult rat ventricular cardiomyocytes were subjected to simulated ischemia/reperfusion to probe mechanism. SAHA reduced infarct size and partially rescued systolic function when administered either before surgery (pretreatment) or solely at the time of reperfusion. SAHA plasma concentrations were similar to those achieved in patients with cancer. In the infarct border zone, SAHA increased autophagic flux, assayed in both rabbit myocardium and in mice harboring an RFP-GFP-LC3 transgene. In cultured myocytes subjected to simulated ischemia/reperfusion, SAHA pretreatment reduced cell death by 40%. This reduction in cell death correlated with increased autophagic activity in SAHA-treated cells. RNAi-mediated knockdown of ATG7 and ATG5, essential autophagy proteins, abolished SAHA's cardioprotective effects. CONCLUSIONS - : The US Food and Drug Administration-approved anticancer histone deacetylase inhibitor, SAHA, reduces myocardial infarct size in a large animal model, even when delivered in the clinically relevant context of reperfusion. The cardioprotective effects of SAHA during ischemia/reperfusion occur, at least in part, through the induction of autophagic flux.

KW - Autophagy

KW - cell death

KW - histone deacetylases

KW - myocardial infarction

KW - reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=84895923936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895923936&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.113.002416

DO - 10.1161/CIRCULATIONAHA.113.002416

M3 - Article

C2 - 24396039

AN - SCOPUS:84895923936

VL - 129

SP - 1139

EP - 1151

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 10

ER -